WO2013074048A3 - Tablet forms comprising quetiapine fumarate - Google Patents

Tablet forms comprising quetiapine fumarate Download PDF

Info

Publication number
WO2013074048A3
WO2013074048A3 PCT/TR2012/000129 TR2012000129W WO2013074048A3 WO 2013074048 A3 WO2013074048 A3 WO 2013074048A3 TR 2012000129 W TR2012000129 W TR 2012000129W WO 2013074048 A3 WO2013074048 A3 WO 2013074048A3
Authority
WO
WIPO (PCT)
Prior art keywords
quetiapine fumarate
tablet forms
quetiapine
fumarate
tablet
Prior art date
Application number
PCT/TR2012/000129
Other languages
French (fr)
Other versions
WO2013074048A2 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2013074048A2 publication Critical patent/WO2013074048A2/en
Publication of WO2013074048A3 publication Critical patent/WO2013074048A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to formulations formulated in tablet form comprising quetiapine fumarate and preparation thereof.
PCT/TR2012/000129 2011-08-08 2012-08-08 Tablet forms comprising quetiapine fumarate WO2013074048A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2011/07833 2011-08-08
TR201107833 2011-08-08

Publications (2)

Publication Number Publication Date
WO2013074048A2 WO2013074048A2 (en) 2013-05-23
WO2013074048A3 true WO2013074048A3 (en) 2013-07-11

Family

ID=47678974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2012/000129 WO2013074048A2 (en) 2011-08-08 2012-08-08 Tablet forms comprising quetiapine fumarate

Country Status (1)

Country Link
WO (1) WO2013074048A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104840442B (en) * 2015-05-15 2018-05-04 浙江永宁药业股份有限公司 A kind of sustained-release tablet containing quetiapine fumarate and preparation method thereof
CN108586385B (en) * 2017-12-26 2020-03-20 山东安信制药有限公司 Method for preparing large-particle-size quetiapine fumarate
CN109001353B (en) * 2018-10-29 2021-06-11 湖南洞庭药业股份有限公司 Quetiapine fumarate tablet pharmaceutical composition and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080065A1 (en) * 2002-03-20 2003-10-02 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
WO2010066342A1 (en) * 2008-11-26 2010-06-17 Krka Quetiapine composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
DE102008046650A1 (en) 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapine-containing prolonged-release tablet

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080065A1 (en) * 2002-03-20 2003-10-02 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
WO2010066342A1 (en) * 2008-11-26 2010-06-17 Krka Quetiapine composition

Also Published As

Publication number Publication date
WO2013074048A2 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
HK1223835A1 (en) Concentrated protein formulations and uses thereof
HUE061728T2 (en) Anti-il13 antibody formulations
IL227626A0 (en) Il -17 and ifn - gamma inhibitior compounds, compositions comprising the same and uses thereof
WO2011093824A3 (en) Effervescent formulations comprising cefaclor
PT2605757E (en) Nalbuphine-based formulations and uses thereof
PT2672981T (en) Multiparticulate l-menthol formulations and related methods
ZA201307191B (en) Antiperspirant active compositions and manufacturing thereof
HK1198137A1 (en) Disinfecting formulations and uses thereof
EP2753179A4 (en) Topical itraconazole formulations and uses thereof
EP2775831A4 (en) Pharmaceutical compositions and uses thereof
ZA201402452B (en) Novel pyrimethanil formulations and uses thereof in the treatment of crops
HK1207563A1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
EP2672837A4 (en) Nutritional compositions and uses thereof
WO2013074048A3 (en) Tablet forms comprising quetiapine fumarate
WO2013064388A3 (en) Cosmetic formulation containing n-acyl-phytosphingosine
MX2014006201A (en) Imatinib solid dosage forms reconstituted just before use.
IL229206A0 (en) Composition and tablet comprising raltegravir
IL228519A (en) Preparation of 3,5-dioxohexanoate ester in two steps
CA141926S (en) Dispenser for cleaning composition
AU2011900451A0 (en) Nutritional compositions and uses thereof
AU2011901447A0 (en) Prophylactic and therapeutic compositions
AP2011006026A0 (en) Medicinal and herbal composition.
AU2011900931A0 (en) Pharmaceutical compositions and use thereof
GB201113314D0 (en) Formulations and processes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12823052

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12823052

Country of ref document: EP

Kind code of ref document: A2